This is one of our possible next regimen until I read the entire article below. She has Pi3K mutation but also ESR1 mutation at Y537S. Still nothing is certain in MBC, only toxicity side effects are. Do we risk certain toxicity (particularly in light of covid raging) for a chance of it might still work?
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
https://www.nature.com/articles/s43018-020-0047-1
Linear Mode
